Advanced searches left 3/3

Metastatic adenocarcinoma - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 06 February 2022

* If you want to update the article please login/register

Phase II Trial of In Situ Tumor Vaccination Using Durvalumab and "Booster" Radiation Therapy in Patients With Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Through First-line Chemotherapy

This is a single-institution phase II study of Durvalumab combined with Radiation Therapy for metastatic pancreatic cancer patients who have undergone chemotherapy by first-line chemotherapy. Pancreatic cancer patients who have undergone second-line or greater chemotherapy in the metastatic setting are not eligible. Durvalumab 1500 mg IV every four weeks will be introduced and continued during RT and afterwards until the patient experiences either unacceptable toxicity or disease progression, depending on the patient's first. Patients must have at least three radiographically measurable pancreatic cancer lesions in several organs that have not been treated for RT, two of which will be treated with RT.

Source link: https://clinicaltrials.gov/ct2/show/NCT03490760


A Phase II Study of FOLFIRINOX Combined With the Glycogen Synthase Kinase-3 Beta (GSK-3 β) Inhibitor 9-ING-41 and the Transforming Growth Factor-β (TGF-β) Inhibitor Losartan in Patients With Untreated Metastatic Adenocarcinoma

FOLFIRINOX is a multi-institutional, open label, four-arm, non-comparator Phase 2 study of FOLFIRINOX in conjunction with 9-ING-41 and losartan for the care of adult patients with untreated metastatic pancreatic adenocarcinoma. Before starting the main portion of the investigation, the Safety Run-In phase will demonstrate the side effects from the study's research's development to its safety. Losartan has not been approved for pancreatic adenocarcinoma therapy by the FDA, but other uses have been permitted. FOLFIRINOX has been approved by the FDA as a treatment option for pancreatic adenocarcinoma. The GSK-3 enzyme aids tumor cells to grow and become resistant to chemotherapy drugs. This research is looking at whether stopping the use of GSK-311 with 9-ING-41 may help standard of care chemotherapy drugs recover their effectiveness in treating cancers in patients where chemotherapy therapy has been limited or ineffective in just a minority of patients. FOLFIRINOX is a combination of four chemotherapy agents that may be able to reduce pancreatic adenocarcinoma tumors. Losartan is a drug used to reduce blood pressure. Losartan has also been shown to reduce TGF- function in pancreatic adenocarcinoma. The cancer cells are thought to be resistant to chemotherapy after suppression of TGF- function. This analysis will determine if blocking GSK-3 activity using 9-ING-41 and blocking TGF- signal transfer using Losartan may cause cancer cell resistance to FOLFIRINOX chemotherapy. The screening for eligibility and study management, as well as evaluations and follow-up visits, was among the study's findings and findings.

Source link: https://clinicaltrials.gov/ct2/show/NCT05077800

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions